Research programme: CD3 antibody therapeutics - Ligand Pharmaceuticals

Drug Profile

Research programme: CD3 antibody therapeutics - Ligand Pharmaceuticals

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crystal Bioscience
  • Developer Ligand Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 27 Jul 2016 Research programme: CD3 antibody therapeutics - Crystal Bioscience is available for licensing as of 27 Jul 2016.
  • 27 Jul 2016 Early research in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top